多参数磁共振成像诊断前列腺癌的循证指南推荐:加拿大安大略癌症治疗中心临床实践指南
该临床实践指南聚焦多参数磁共振成像(mpMRI)在前列腺癌诊断中的两项应用:对活检初治且临床显著前列腺癌(CSPC)风险升高者,不推荐将mpMRI后靶向活检作为标准诊疗;对既往经直肠超声引导系统活检阴性但CSPC风险持续升高者,可考虑mpMRI后靶向活检以检出更多CSPC患者。
要点
- 活检初治且CSPC风险升高者,mpMRI后靶向活检不应被视为标准诊疗。
- 既往TRUS系统活检阴性但CSPC风险持续升高者,可考虑mpMRI后靶向活检。
- 指南基于实践指南开发循环方法,检索MEDLINE、EMBASE等数据库并完成内外部评审。
核心结论
- 对活检初治且CSPC风险升高者,mpMRI后靶向活检不应被视为标准诊疗,需未来研究确定其价值。
- 对既往TRUS引导系统活检阴性且CSPC风险持续升高者,可考虑mpMRI后靶向活检以检出更多CSPC患者。
研究设计与样本
- 本指南为加拿大安大略癌症治疗中心(Cancer Care Ontario)临床实践指南,采用实践指南开发循环方法制定。
- 检索MEDLINE、EMBASE、Cochrane图书馆(1997年至2014年4月)、主要指南网站及相关年会摘要(2011年至2014年),并进行内外部评审。
诊断标准与关键数值
- 推荐1:对活检初治且CSPC风险升高(依据前列腺特异抗原水平和/或列线图)者,mpMRI后靶向活检不应被视为标准诊疗。
- 推荐2:对既往TRUS引导系统活检阴性且CSPC风险较前次活检升高(如PSA持续升高和/或直肠指检发现变化)者,可考虑mpMRI后靶向活检。
临床应用与阅片要点
- 推荐1:活检初治且CSPC风险升高者,mpMRI后靶向活检不应被视为标准诊疗。
- 推荐2:既往TRUS引导系统活检阴性且CSPC风险持续升高者,可考虑mpMRI后靶向活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy. The methods of the Practice Guideline Development Cycle were used. MEDLINE, EMBASE, the Cochrane Library (1997‒April 2014), main guideline websites, and relevant annual meeting abstracts (2011‒2014) were searched. Internal and external reviews were conducted. The two main recommendations are: Recommendation 1: In patients with an elevated risk of CSPC (according to prostate-specific antigen [PSA] levels and/or nomograms) who are biopsy-naïve: mpMRI followed by targeted biopsy (biopsy directed at cancer-suspicious foci detected with mpMRI) should not be considered the standard of care.Data from future research studies are essential and should receive high-impact trial funding to determine the value of mpMRI in this clinical context.Recommendation 2: In patients who had a prior negative TRUS-guided systematic biopsy and demonstrate an increasing risk of having CSPC since prior biopsy (e.g., continued rise in PSA and/or change in findings from digital rectal examination): mpMRI followed by targeted biopsy may be considered to help in detecting more CSPC patients compared with repeated TRUS-guided systematic biopsy.
引用
- Haider MA, Yao X, Loblaw A, et al. Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline. Can Urol Assoc J. 2017. PMID: 28163805. doi:10.5489/cuaj.3968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。